CLGM
TBPH icon

Capitolis Liquid Global Markets’s Theravance Biopharma TBPH Stock Holding History

Capitolis Liquid Global Markets’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-127,200
Closed -$1.4M – 311
2025
Q2 		$1.4M Buy
+127,200
New +$1.24M 0.01% 233

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Capitolis Liquid Global Markets's TBPH Position: Q3 2025 in Review

Capitolis Liquid Global Markets sold out of Theravance Biopharma (TBPH) in Q3 2025, closing a stake of 127,200 shares — an estimated $1.4M sold.

Capitolis Liquid Global Markets first reported a position in TBPH in Q2 2025 and held it in 1 quarter. The position peaked at $1.4M in Q2 2025. 162 funds tracked by Wall St. Rank hold TBPH as of Q3 2025.

  • Capitolis Liquid Global Markets reported no remaining Theravance Biopharma position as of Q3 2025 after selling out during the quarter.
  • Capitolis Liquid Global Markets sold 127,200 Theravance Biopharma shares in Q3 2025, an estimated $1.4M.
  • Capitolis Liquid Global Markets first reported a position in Theravance Biopharma in Q2 2025 and held it in 1 quarter.
  • Capitolis Liquid Global Markets's Theravance Biopharma position peaked at $1.4M in Q2 2025.
  • 162 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2025.

Based on Capitolis Liquid Global Markets's 13F filing for Q3 2025, filed 14 Nov 2025.